Format

Send to

Choose Destination
Anticancer Res. 2016 Dec;36(12):6243-6248.

A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.

Author information

1
Department of Cell & Molecular Biology, San Diego State University, San Diego, CA, U.S.A.
2
Vaxiion Therapeutics, San Diego, CA, U.S.A.
3
Department of Chemical and Biological Engineering, Tulane University, New Orleans, LA, U.S.A. Godbey@Tulane.edu.

Abstract

BACKGROUND/AIM:

VAX014 minicells (VAX014) have been previously characterized as an integrin-specific oncolytic biotherapeutic agent. The present study was designed to evaluate the potential of VAX014 as an immediate post-operative intravesical adjuvant therapy in the treatment of non-muscle invasive bladder cancer (NMIBC).

MATERIALS AND METHODS:

The ability of VAX014 to kill a panel of dissociated urothelial carcinoma cell lines was tested in vitro. In vivo experiments were conducted using a single intravesical dose of VAX014 in the anti-implantation variation of the MB49 syngeneic orthotopic bladder cancer model with tumor implantation and overall survival rates serving as study endpoints.

RESULTS:

VAX014 rapidly killed dissociated urothelial carcinoma cells, while single dose in vivo pharmacology studies demonstrated the dose-dependent ability of VAX014 to prevent tumor implantation and development, ultimately resulting in a significant survival advantage compared to controls.

CONCLUSION:

These results suggest that VAX014 holds potential as an immediate post-operative adjuvant therapy in NMIBC.

KEYWORDS:

Non-muscle invasive bladder cancer; invasin; minicells; perfringolysin O

PMID:
27919942
DOI:
10.21873/anticanres.11218
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center